New Treatment Options in Advanced Melanoma

 

As part of ESMO's continuous commitment to offering beneficial educational material relevant to your work and practice in order to receive your certificate, please complete the Evaluation Survey, which will take approximately 5 minutes. Please indicate which rating reflects your answer.

Questions marked with are required.

1. Did your participation in this E-Learning module allow you to understand key signaling pathways dysregulated in melanoma patients and mechanisms of actions of new agents targeting these disruptions? (1-not at all; 5-a lot)

2. Did your participation in this E-Learning module provide you with an update on efficacy and toxicity data of the new therapies in melanoma patients? (1-not at all; 5-a lot)

3. Did your participation in this E-Learning module allow you to understand the issues surrounding the treatment of patients with advanced melanoma and put latest data into clinical context? (1-not at all; 5-a lot)

4. Please, provide your overall rating of the quality of the education offered by this E-Learning module. (1-poor; 5-excellent)

5. How would you rate the interactivity level offered in the E-Learning material? (1-poor; 5-excellent)

6. Was the information useful and relevant to your work and practice? (1-not at all; 5-completely)

7. Do you feel that the information presented was well balanced and supported by adequate evidence? (1-not at all; 5-absolutely)

8. If you would like to add your personal comments or make suggestions to improve future ESMO E-Learning material, please write in the box below: